Powder: -20°C for 3 years | In solvent: -80°C for 1 year
L-Buthionine-(S,R)-sulfoximine hydrochloride 是一种有效的、可细胞渗透的,作用快的 G-谷氨酸半胱氨酸合成酶 (γ-glutamylcysteine synthetase, γ-GCS)的不可逆抑制剂并可耗尽细胞内的谷胱甘肽水平,在黑色素瘤、乳腺癌和卵巢癌标本上的 IC50值分别为1.9 μM、8.6 μM 和 29 μM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | 待询 | 10-14周 | ||
50 mg | 待询 | 10-14周 |
产品描述 | L-Buthionine-(S,R)-sulfoximine hydrochloride is a potent, cell-permeable, fast-acting and irreversible inhibitor of G-glutamylcysteine synthetase (γ-GCS) and depletes cellular glutathione levels. L-Buthionine-(S,R)-sulfoximine has IC50s of 1.9 μM, 8.6 μM, and 29 μM in melanoma, breast and ovarian tumor specimens, respectively [1] [2]. |
体外活性 | L-Buthionine-(S,R)-sulfoximine synergistically enhanced BCNU activity against melanoma cell lines and human tumors. BSO (50 μM) treatment for 48 hr causes a 95% decrease in ZAZ and M14 melanoma cell line GSH levels, and a 60% decrease in GST enzyme activity. GST-μ protein and mRNA levels are significantly reduced in both cell lines. GST-π expression is unaffected. BSO enhancement of alkylator action may be related in part to down regulation of GST [1]. L-Buthionine-(S,R)-sulfoximine (BSO) induces oxidative stress in a cell by irreversibly inhibiting gamma-glutamylcysteine synthetase which is an essential enzyme for the synthesis of glutathione (GSH) [2]. L-Buthionine-(S,R)-sulfoximine (BSO) was demonstrated to induce ferroptosis in cancer cells [3]. |
体内活性 | BSO treatment resulted in a significantly increased frequency of DNA deletions and decreased concentrations of GSH and cysteine. BSO treatment reduced GSH concentration in mouse fetuses by 27% and 55% at 2 mM and 20 mM BSO doses, respectively, compared with untreated mice. Co-treatment with 2 mM BSO and 20 mM NAC depleted GSH to a similar extent as 2 mM BSO, consistent with the function of BSO inhibiting the g-GCS enzyme indispensable for GSH synthesis [2]. |
分子量 | 258.77 |
分子式 | C8H19ClN2O3S |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
L-Buthionine-(S,R)-sulfoximine hydrochloride Inhibitor inhibitor inhibit